Efficacy Study – HSHFD+STZ-Induced Diabetic Kidney Disease Model

The contract outlines a commissioned efficacy study to evaluate the impact of an NNMT inhibitor in a mouse model of diabetic kidney disease induced by a high-sodium, high-fat diet combined with streptozotocin. The study requires comprehensive metabolic monitoring throughout the treatment period, precise dosing regimens, and systematic collection of tissue samples for downstream analysis. Endpoint evaluation will include detailed assessment of renal function, histopathological changes, and molecular markers associated with disease progression and therapeutic response. All procedures must adhere to standardized protocols to ensure data reliability and reproducibility, with results intended to support further development of the inhibitor as a potential therapeutic agent. The work is being pursued under a subcontract agreement issued by the National Institutes of Health through the Department of Health and Human Services, classified under NAICS code 541690 for other scientific research and development services. The solicitation was posted on August 4, 2026, with a response deadline of August 19, 2026. The contract does not specify a place of performance or point of contact, and no set-aside provisions are indicated. The project is positioned as a critical preclinical step in advancing an NNMT-targeted intervention for diabetic kidney disease, with findings expected to inform future clinical translation and funding decisions.